Success Metrics

Clinical Success Rate
91.1%

Based on 113 completed trials

Completion Rate
91%(113/124)
Active Trials
8(5%)
Results Posted
37%(42 trials)
Terminated
11(7%)

Phase Distribution

Ph phase_1
19
12%
Ph not_applicable
18
11%
Ph phase_2
37
23%
Ph phase_3
47
29%
Ph early_phase_1
4
2%
Ph phase_4
34
21%

Phase Distribution

23

Early Stage

37

Mid Stage

81

Late Stage

Phase Distribution159 total trials
Early Phase 1First-in-human
4(2.5%)
Phase 1Safety & dosage
19(11.9%)
Phase 2Efficacy & side effects
37(23.3%)
Phase 3Large-scale testing
47(29.6%)
Phase 4Post-market surveillance
34(21.4%)
N/ANon-phased studies
18(11.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.3%

113 of 134 finished

Non-Completion Rate

15.7%

21 ended early

Currently Active

8

trials recruiting

Total Trials

161

all time

Status Distribution
Active(11)
Completed(113)
Terminated(21)
Other(16)

Detailed Status

Completed113
unknown16
Terminated11
Withdrawn10
Recruiting8
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
161
Active
8
Success Rate
91.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (2.5%)
Phase 119 (11.9%)
Phase 237 (23.3%)
Phase 347 (29.6%)
Phase 434 (21.4%)
N/A18 (11.3%)

Trials by Status

not_yet_recruiting21%
terminated117%
withdrawn106%
recruiting85%
enrolling_by_invitation11%
unknown1610%
completed11370%

Recent Activity

Clinical Trials (161)

Showing 20 of 161 trialsScroll for more
NCT05562466Phase 3

A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

Recruiting
NCT05509933Phase 3

Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation

Recruiting
NCT06596252Phase 3

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

Recruiting
NCT07528820Not Applicable

Inflammatory Profiles, Histopathological Features, and Remodeling Factors in Chronic Rhinosinusitis With Nasal Polyps

Not Yet Recruiting
NCT06334575Phase 4

Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels

Recruiting
NCT05839756Not Applicable

Predicting Post Extubation Stridor After Maxillomandibular Fixation

Recruiting
NCT06855043Phase 1

Little Lungs Study

Not Yet Recruiting
NCT04294641Phase 2

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

Completed
NCT05878093Phase 3

Dupilumab in Chinese Adult Participants With CRSwNP

Completed
NCT06841406Phase 4

Budesonide as a Treatment for Functional Dyspepsia

Recruiting
NCT06719622Phase 2

Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/or Stomach And/or Duodenum

Enrolling By Invitation
NCT06268301Phase 1

A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension) in the Body of Healthy Adults

Completed
NCT06595121Phase 1

Bioequivalence of IMP 08P1707F0 Relative to Pulmicort® (1.0 Mg/2 Ml Suspension)

Completed
NCT05444543Phase 4

Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis)

Completed
NCT03615742Phase 4

Diesel Exhaust Induces Glucocorticoid Resistance

Recruiting
NCT04964414Phase 1

Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19

Terminated
NCT06367881Phase 1

Assessment Of Dose-Dependent Immunomodulatory Effect Of Alveofact With or Without Steroisd In Neonatal RDS

Recruiting
NCT04952389Not Applicable

Acupuncture Therapy for COVID-Related Olfactory Loss

Completed
NCT06158893Phase 4

Comparison of Preoperative Inhaled Budesonide With Salbutamol on the Respiratory Adverse Effects in Children Undergoing Tonsillectomy

Unknown
NCT04892732

Replication of the D58 Asthma Trial in Healthcare Claims Data

Completed

Drug Details

Intervention Type
DRUG
Total Trials
161